76 results
8-K
EX-99.1
IBRX
ImmunityBio Inc
23 Apr 24
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class
6:17am
innovative treatment. More information for patients and healthcare professionals will be available on Anktiva.com.
Conference Call and Webcast
8-K
IBRX
ImmunityBio Inc
23 Feb 24
Departure of Directors or Certain Officers
9:28pm
and compliance with healthcare laws.
The above description of the Code of Ethics does not purport to be complete and is qualified in its entirety by reference
8-K
EX-99.1
of4x2ste9ffc3 0ww8ek
2 Jan 24
ImmunityBio Announces $320 Million Investment by Oberland
6:08am
8-K
EX-1.1
0c4 axw4qg
21 Jul 23
ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors
6:04am
8-K
EX-10.1
gj7ektcqpel15g6bo
21 Jul 23
ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors
6:04am
8-K
EX-1.1
96512luqr8 11
12 Dec 22
ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor
9:07am
8-K
EX-10.1
jgh68y dwniwj
12 Dec 22
ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor
9:07am
8-K
f6i2eeh yt9veh7pu7
15 Nov 22
Regulation FD Disclosure
8:42am
424B5
pnod65uf q89iw
26 May 22
Prospectus supplement for primary offering
3:33pm